Bio-Rad’s New Clarity™ Western ECL Substrate Delivers Performance without Sacrifice

Clarity western ECL substrate
By combining superior performance at an affordable price, Clarity western ECL offers researchers a nearly universal substrate option.

Western Blotting Detection Substrate Takes the Guesswork out of Selection

Hercules, CA — October 1, 2012 — Bio-Rad Laboratories, Inc. announces the launch of its new chemiluminescent detection reagent, Clarity western ECL substrate. Ideally suited to meet the diverse needs of researchers utilizing western blotting, Bio-Rad’s Clarity substrate provides excellent results for both high- and low-expression proteins, using either film or digital detection systems.

Choosing the right western blotting detection substrate can be difficult. Ideally, researchers would like to use a single high-performance substrate that works well for all types of blots. In practice, most substrates on the market today are highly specialized. Some substrates work well for the detection of low-expression proteins, whereas others offer less robust performance but are less expensive. Protein expression levels are often difficult or impossible to determine prior to detection, in which case the scientist must choose a substrate and hope for the best outcome.

“The Clarity western ECL substrate takes the guesswork out of substrate selection and eliminates the risk of choosing incorrectly,” said Ryan Short, western blotting product manager at Bio-Rad. “By combining superior performance and an affordable price, Clarity substrate offers researchers nearly universal application.”

The highly versatile Clarity western ECL substrate was designed for blots using nitrocellulose, PVFD, and low-fluorescence PVDF and can be used to detect both high- and low-abundance proteins when using film or CCD imaging systems for blot detection. Clarity ECL substrate has a one-year shelf life and is stored at room temperature, allowing the researcher to store it conveniently at hand on the bench. 

Clarity ECL substrate offers the following advantages with respect to sensitivity, background, and signal duration:

  • Sensitivity — detects proteins at mid-to-low femtogram levels
  • Low background   generates clean-looking blots with bright bands of interest and low background luminescence
  • Long signal duration — provides exceptionally long signal duration (24 hours), giving researchers the flexibility to take longer exposure times or multiple exposures before the signal starts to fade

For product details or to order the Clarity western ECL substrate, visit

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained  at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit‑

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact: 
Ryan Short
Bio-Rad Laboratories, Inc.

Ken Li
Chempetitive Group
312-997-2436 x 112